“Pulse Width Modulation might be described as an open-ended conversation. When we first launched PWM in the USA, the system only controlled sections. However, it wasn’t long before people started asking if those same valves could be used for controlling individual nozzles.

“From its earliest iteration, PinPoint was invented to stretch the capability of what could be achieved with a spray system. The latest goal for our PinPoint III Envelop system is high-resolution, independent, individual-nozzle control. But what exactly does this mean?

“The amount of Information that we can measure and control is increasing. The question is how can we better control? The answer is the CapMod.

“The CapMod is an auxiliary processing unit, (imagine a computer that plugs into another computer to boost performance) that operates with the PinPoint III system. It allows us to bypass the limitations of other systems to perform applications that were previously not possible. It is still in development, and what we will ultimately be able to do with it is still not set in stone.”

“Probably the most nearby feature is individual nozzle variable rate control. We will be able to adjust the duty cycle to apply a desired dose (within the limitations of a given nozzle size/speed range) to meet the target according to a prescription map. This will likely be most utilised for fertilizer applications, but the utility would not be limited to that.

“Other features will be tied to existing and future data layers, which are what the system reads to do its job. We are only beginning to take advantage of all the information that the sprayer has available. If we can map more than simply applied rate, but also applied pressure, boom height, and more, we may be able to move the whole of the application industry into the future by enabling decisions to be made with more and better information.

“Currently, the CapMod will require an additional display (an iPad) to operate. Future development may offer alternatives. We are moving forward with testing and are planning trials in 2025.”

We’ll update you on our progress…